Nicholas H. Chakiryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicholas H. Chakiryan has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Brandon J. Manley
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
19 shared publications - Anders E. Berglund
Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, USA
18 shared publications - Abraham Ari Hakimi
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA
17 shared publications - Fengshen Kuo
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
16 shared publications - Phillip M. Rappold
Urology Service, Department Of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
16 shared publications - Albert Reising
12Novartis Oncology, New Hanover, New Jersey
15 shared publications
Latest Publications
- 1 August 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (2) , 216-217
Editorial Comment
- 1 August 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (2) , 216-217
Editorial Comment
- 1 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (5) , 574-575
Editorial Comment
- 1 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (5) , 574-575
Editorial Comment
- 1 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (5) , 533-534
Editorial Comment
- 1 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (5) , 533-534
Editorial Comment
- Open Access
Genomic and Molecular Associations with Preoperative Immune Checkpoint Inhibition in Patients with Stage III Clear Cell Renal Cell Carcinoma
Background and Objective: Patients with stage III clear cell renal cell carcinoma (ccRCC) have a high risk for disease recurrence post-nephrectomy. To mitigate overtreatment, there is a pressing need to determine who benefits from immune checkpoint inhibition (ICI) around the time of surgical resection. We performed digital spatial analysis of both gene and protein expression in stage III ccRCC tumors, some of which had preoperative ICI exposure. Methods: Nephrectomy specimens from stage III ccRCC patients were analyzed using the Nanostring GeoMx Digital Spatial Profiler. Differential expression analysis was performed and validated using NCT02210117 trial data to identify genes associated with both ICI and clinical response. A gene score was then generated to predict overall survival in patients from The Cancer Genome Atlas (TCGA). Key Findings and Limitations: In a small cohort of 19 patients, RNA expression significantly differed based on preoperative ICI exposure and recurrence status—CD8+ effector and central-memory T-cell signatures were less prevalent in the treatment-naïve with recurrence group. Three out of four patients with preoperative immune checkpoint inhibition recurred. External validation yielded a four-gene set (GZMK, GZMA, ITGAL, and IL7R), where higher expression levels predicted better overall survival in the TCGA cohort (p = 0.005). Conclusions and Clinical Implications: Preoperative ICI favorably altered the tumor microenvironment to resemble that of treatment-naïve patients without recurrence but did not translate to improved survival. Upon external validation, the genes GZMK, GZMA, ITGAL, and IL7R were modifiable with ICI and associated with improved overall survival. Further investigation is needed to assess if patients with low baseline expression of these genes may benefit from ICI around the time of surgery.
Open AccessGenomic and Molecular Associations with Preoperative Immune Checkpoint Inhibition in Patients with Stage III Clear Cell Renal Cell Carcinoma
Background and Objective: Patients with stage III clear cell renal cell carcinoma (ccRCC) have a high risk for disease recurrence post-nephrectomy. To mitigate overtreatment, there is a pressing need to determine who benefits from immune checkpoint inhibition (ICI) around the time of surgical resection. We performed digital spatial analysis of both gene and protein expression in stage III ccRCC tumors, some of which had preoperative ICI exposure. Methods: Nephrectomy specimens from stage III ccRCC patients were analyzed using the Nanostring GeoMx Digital Spatial Profiler. Differential expression analysis was performed and validated using NCT02210117 trial data to identify genes associated with both ICI and clinical response. A gene score was then generated to predict overall survival in patients from The Cancer Genome Atlas (TCGA). Key Findings and Limitations: In a small cohort of 19 patients, RNA expression significantly differed based on preoperative ICI exposure and recurrence status—CD8+ effector and central-memory T-cell signatures were less prevalent in the treatment-naïve with recurrence group. Three out of four patients with preoperative immune checkpoint inhibition recurred. External validation yielded a four-gene set (GZMK, GZMA, ITGAL, and IL7R), where higher expression levels predicted better overall survival in the TCGA cohort (p = 0.005). Conclusions and Clinical Implications: Preoperative ICI favorably altered the tumor microenvironment to resemble that of treatment-naïve patients without recurrence but did not translate to improved survival. Upon external validation, the genes GZMK, GZMA, ITGAL, and IL7R were modifiable with ICI and associated with improved overall survival. Further investigation is needed to assess if patients with low baseline expression of these genes may benefit from ICI around the time of surgery.
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (1) , 66-67
Editorial Comment
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (1) , 66-67
Editorial Comment
- 1 December 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 214 (6) , 611
Editorial Comment
- 1 December 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 214 (6) , 611
Editorial Comment
- Open Access
Genomic and molecular associations with preoperative immune checkpoint inhibition in patients with stage III clear cell renal cell carcinoma
Purpose: Patients with stage III clear cell renal cell carcinoma are at high risk for recurrence after nephrectomy. To mitigate overtreatment, there is a pressing clinical need to determine which patients benefit most from perioperative immune checkpoint inhibition. We performed a multimodal digital spatial analysis of gene and protein expression in stage III primary renal cell carcinomas, a subset of which had preoperative immune checkpoint inhibition exposure. Materials and Methods: Surgically resected tumors from stage III clear cell renal cell carcinoma patients were analyzed using the Nanostring GeoMx Digital Spatial Profiler. Differential expression analysis was performed and validated using NCT02210117 trial data to identify genes associated with immune checkpoint blockade and clinical response. A gene score was then generated to predict overall survival in patients from The Cancer Genome Atlas. Results: Among 19 patients, RNA expression significantly differed based on preoperative immune checkpoint blockade and recurrence – CD8+ effector and central-memory T-cell signatures were less prevalent in the treatment-naïve with recurrence group. Three out of four patients with preoperative immune checkpoint inhibition had recurrence. External validation yielded a 4-gene set ( GZMK, GZMA, ITGAL , and IL7R ); higher gene expression levels predicted better overall survival in The Cancer Genome Atlas cohort (p=0.005). Discussion: Preoperative immune checkpoint blockade favorably altered the tumor microenvironment to resemble that of treatment-naïve patients without recurrence. However, this did not translate to better clinical outcomes. On external validation, the genes GZMK, GZMA, ITGAL , and IL7R were modifiable with immune checkpoint inhibition and associated with improved survival. Further investigation to assess if patients with low baseline expression of these genes may particularly benefit from perioperative immune checkpoint blockade is warranted.
Open AccessGenomic and molecular associations with preoperative immune checkpoint inhibition in patients with stage III clear cell renal cell carcinoma
Purpose: Patients with stage III clear cell renal cell carcinoma are at high risk for recurrence after nephrectomy. To mitigate overtreatment, there is a pressing clinical need to determine which patients benefit most from perioperative immune checkpoint inhibition. We performed a multimodal digital spatial analysis of gene and protein expression in stage III primary renal cell carcinomas, a subset of which had preoperative immune checkpoint inhibition exposure. Materials and Methods: Surgically resected tumors from stage III clear cell renal cell carcinoma patients were analyzed using the Nanostring GeoMx Digital Spatial Profiler. Differential expression analysis was performed and validated using NCT02210117 trial data to identify genes associated with immune checkpoint blockade and clinical response. A gene score was then generated to predict overall survival in patients from The Cancer Genome Atlas. Results: Among 19 patients, RNA expression significantly differed based on preoperative immune checkpoint blockade and recurrence – CD8+ effector and central-memory T-cell signatures were less prevalent in the treatment-naïve with recurrence group. Three out of four patients with preoperative immune checkpoint inhibition had recurrence. External validation yielded a 4-gene set ( GZMK, GZMA, ITGAL , and IL7R ); higher gene expression levels predicted better overall survival in The Cancer Genome Atlas cohort (p=0.005). Discussion: Preoperative immune checkpoint blockade favorably altered the tumor microenvironment to resemble that of treatment-naïve patients without recurrence. However, this did not translate to better clinical outcomes. On external validation, the genes GZMK, GZMA, ITGAL , and IL7R were modifiable with immune checkpoint inhibition and associated with improved survival. Further investigation to assess if patients with low baseline expression of these genes may particularly benefit from perioperative immune checkpoint blockade is warranted.
- 14 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
Editorial Comment
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (4) , 465
Editorial Comment
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (4) , 465
Editorial Comment